There are tons of ways to generate "strong candidates for drug design." This is definitely not the bottleneck in drug discovery and development. The hard problem is vetting and developing these ideas to the point of having a commercially viable drug. That is still a very empirical process.
replyBecause it's completely meaningless without validation, and even with validation, not really any better than the state of the art protein generation models. Which are also mostly just nice to have because coming up with a candidate is generally quite easy.
replyThe rate limiting steps are generally testing, or characterizing. Not designing protein binders.
It's selective reporting. Says 'in one example', but out of how many, is that one-shot, or is it a random result out of 100. It's a marketing doc.
replydeleted
replyWould be funny if anthropic ends up as mostly a pharma company
replyUntil we are able to reliably simulate cells, organs, and entire human bodies in silico, we will not be able to move the needle too much on drug design from an AI stand-point (IMO). Like others pointed out, the massive bottle neck in time and cost in getting a drug to market are far removed from developing drug candidates.
replyDrug design isn't the bottleneck anymore, it's trials. Still cool they can do this with a general purpose model though.
reply